The Study
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies
This study found that older people with more 'Alzheimer's proteins' in their brains tended to forget things faster over time. But it didn't prove that those proteins caused the forgetting — maybe other things like stress, sleep, or genes played a role too. It's like noticing that people who eat more candy often get more cavities — but that doesn't mean candy alone causes cavities.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Scientists tested if a simple blood test for a protein called P-tau217 can tell who will start forgetting things soon — even if they still seem fine.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 565 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means a blood test could identify people at highest risk of Alzheimer’s years before they show clear symptoms, helping doctors target treatments earlier.
- 2People with the highest P-tau217 levels were over 50% likely to start having trouble with daily tasks within 4.5 years — even better than amyloid scans.
- 3The blood test also predicted decline in people with amyloid levels below the usual 'positive' threshold.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Journal of Prevention of Alzheimer's Disease
Year
2024
Authors
R. Sperling, M. Donohue, R. Rissman, K. Johnson, D. Rentz, J. Grill, J. Heidebrink, C. Jenkins, G. Jimenez-Maggiora, O. Langford, A. Liu, R. Raman, R. Yaari, K. Holdridge, J. Sims, P. Aisen
Related Content
Claims (6)
The buildup of amyloid-beta proteins starts the disease process in Alzheimer's, but the spread of tau proteins is more closely linked to worsening memory and thinking problems.
In older adults without cognitive impairment, higher levels of P-tau217 in the blood predict future decline in thinking and memory skills, even when brain amyloid levels are below the standard imaging threshold for Alzheimer's disease.
In older adults with early Alzheimer's pathology but no cognitive symptoms, higher levels of tau protein in the outer brain regions predict a faster decline in thinking and memory over 4.5 years, more than levels of amyloid protein.
Older adults with no cognitive symptoms but high levels of amyloid and P-tau217 in their blood or brain scans have more than a 50% chance of developing measurable functional decline within 4.5 years.
In older adults without cognitive impairment, initial cognitive test scores predict how quickly their thinking skills will decline over time, even when amyloid and tau biomarker levels are taken into account.
In older adults with early signs of Alzheimer’s brain changes but no cognitive symptoms, higher levels of a specific protein in the blood called phosphorylated tau-217 are linked to a faster loss of memory and thinking skills over 4.5 years, and this protein predicts decline better than brain scans of amyloid.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.